For research use only
| Cat No. | ABC-TC1017 |
| Product Type | Human Nerve Tumors Cell Lines |
| Cell Type | Fibroblast-like |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Brain |
| Product Code | SF-126; SF 126 |
SF-126 glioblastoma cells show fibroblast-like morphology, aneuploidy, lack GFAP due to hypermethylation, and form tumors intracranially in mice.
SF126 is a human glioblastoma multiforme (GBM) cell line originally derived from a pediatric brain tumor. These cells are of neuroepithelial origin and display a polygonal to spindle-shaped morphology under standard culture conditions. SF126 cells exhibit characteristics typical of high-grade astrocytomas, including rapid proliferation, chromosomal aneuploidy, and anchorage-independent growth. Karyotype analysis reveals multiple structural abnormalities and complex chromosomal rearrangements. They are highly tumorigenic in nude mice, forming aggressive intracranial or subcutaneous tumors. SF126 expresses glial markers such as GFAP and S100. This cell line is frequently used to model GBM-related resistance to chemotherapy and radiotherapy. The cells are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, mycoplasma, fungi, yeast, and bacteria.
| Product Code | SF-126; SF 126 |
| Species | Human |
| Cat.No | ABC-TC1017 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Fibroblast-like |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Brain |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Nerve Tumors Cell Lines |
SF126 cells serve as a valuable tool for studying the cell biology of gliomas and are established as a model for human glioblastoma. Their significance lies in their ability to provide insights into various aspects of cellular physiology and chemosensitivity related to gliomas. They offer a platform to evaluate potential therapies, including radiation, for human gliomas, aiding in the development and testing of novel treatment strategies for this aggressive form of brain cancer.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
